Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Agitation in Delirium Management Market, by Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 212.7 million in 2020 and is expected to exhibit a CAGR of 4.3% during the forecast period (2020-2027).

Increasing awareness about the risk factors that are responsible for causing delirium in the patients, is expected to boost the growth of the global agitation in delirium management market over the forecast period. For instance, according to National Center for Biotechnology Information:  November 18, 2020 report, there are two groups of risk factors related to delirium: predisposing and precipitant factors. The following table explains the two factors.

Predisposing Factors Precipitant Factors
Older Age (older than 70 years) Surgery and anesthesia
Dementia High pain levels
Functional disabilities Anemia
Poor Vision and Hearing Infections
Mild cognitive impairment Acute illness
Alcohol use disorder Drugs (sedative-hypnotic agents, anticholinergic, nonbenzodiazepines etc.)

Increasing product approvals by the regulatory authority is expected to increase the growth of the global agitation in delirium management market over the forecast period. For instance, according to the American Journal of Psychiatry: 2019 report, in the year 2016, the U.S. Food and Drug Administration (U.S. FDA) approved 12 second-generation antipsychotic drugs for the management of agitation in delirium as there are no medications approved for the treatment of the same. The approved drugs were risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, brexpiprazole, and clozapine.

Moreover, in 2019, Zydus Cadila announced that it received approval from the U.S. FDA to market Aripiprazole tablets in the strengths of 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.

Global Agitation in Delirium Management Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global agitation in delirium management market over the forecast period. COVID-19 is the recent pandemic outbreak which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), around 135,057,587 cases of the coronavirus disease (COVID-19) were reported on April 11, 2021 across the globe.

Due to the increasing prevalence of COVID-19, key players operating in the agitation in delirium management market as well as other research institutes are focusing on finding the treatment for delirium occurring in COVID-19 positive patients. This is expected to aid in growth of the market over the forecast period. For instance, on February 25, 2021, BioXcel Therapeutics, Inc. initiated the Phase 2 PLACIDITY trial of BXCL501 for the treatment of delirium related agitation. The safety, efficacy, and pharmacokinetics of BXCL501 is being checked on adult patients experiencing agitation in delirium, including in COVID-19 patients in the intensive care unit.

Browse 34 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on Global Agitation in Delirium Management Market, by Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the agitation in delirium management market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/agitation-in-delirium-management-market-4430

Increasing prevalence of diabetes among the population may also increase the risk of agitation in delirium, which is expected to drive growth of the market over the forecast period. For instance, according to NCBI: 2016 report, patients suffering from poorly controlled diabetes have shown to experience hallucinations and delirium due to high blood sugar levels. For instance, according to the Diabetes Research and Clinical Practice: 2019 report, the following graph compares the number of people suffering from diabetes (in percentage) in Egypt in the year 2019 and the estimated number of patients that will be suffering from diabetes in the year 2030 and 2045.

Key Takeaways of the Agitation in Delirium Management Market:

  • The global agitation in delirium management market is expected to exhibit a CAGR of 4.3% over the forecast period (2020-2027), owing to growth in potential markets, especially in Europe. North America accounted for major market share.
  • The government organizations are involved in updating the guidelines for easy identification of agitation in delirium among the patients, such guidelines is expected to increase the growth of the market over the forecast period. For instance, the National Institute for Health and Care Excellence: 2019 report, generated guidelines for diagnosing and treating delirium in people aged 18 and over in hospitals, and in long-term residential care or nursing homes. The guidelines include identifying risk factors of delirium, indicators of delirium at presentation and daily observations, preventing delirium, diagnosing delirium, and treating delirium. The guidelines are directed for: NHS staff responsible for patients in hospital and long-term residential care settings, adult hospital patients, adults in long-term residential care or a nursing home, and family and caregivers of people with or at high risk of developing delirium.
  • Some of the major players operating in the global agitation in delirium management market include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis International AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., and BioXcel Therapeutics, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner